1例贝纳柯克斯体椎体骨髓炎患者的药学监护

doi:10.19803/j.1672-8629.20240221

中国药物警戒 ›› 2024, Vol. 21 ›› Issue (10): 1166-1168.
DOI: 10.19803/j.1672-8629.20240221

1例贝纳柯克斯体椎体骨髓炎患者的药学监护

沈江华¹, 孔超², 潘福敏², 褚燕琦^1,*

¹首都医科大学宣武医院药剂科,北京 100053;
²首都医科大学宣武医院骨科,北京 100053

收稿日期:2024-04-03 出版日期:2024-10-15 发布日期:2024-10-14
通讯作者: ^*褚燕琦,女,硕士,主任药师,重症患者用药安全。E-mail: yanqi0545@sina.com
作者简介:沈江华,女,硕士,副主任药师,老年患者围术期用药安全。
基金资助:
首都卫生发展科研专项重点公关项目（首发2024-1-2012）

Pharmaceutical care of a case with vertebral osteomyelitis of Coxiella burnetiid

SHEN Jianghua¹, KONG Chao², PAN Fumin², CHU Yanqi^1,*

¹Department of Pharmacy, Xuanwu Hospital of Capital Medical University, Beijing 100053, China;
²Department of Orthopedics, Xuanwu Hospital of Capital Medical University, Beijing 100053, China

Received:2024-04-03 Online:2024-10-15 Published:2024-10-14

摘要/Abstract

摘要： 目的通过对1例贝纳柯克斯体椎体骨髓炎患者的病例介绍,探讨临床药师开展特殊感染患者的药学监护的切入点及在罕见病原体导致感染患者治疗过程的作用。方法分析临床药师参与 1 例由贝纳柯克斯体引起腰椎感染患者的治疗过程,协助医生分析患者病史及病原学特点,提出敏感药物治疗方案,并对其持续进行药学监护,协助医生评估治疗效果,并持续调整药物治疗方案。结果及结论 临床药师协助医生制定治疗方案,以特殊病原菌引起罕见部位感染为切入点,对患者开展药学监护,保障患者病情稳定好转。临床药师参与治疗团队可有效保障患者用药安全。

关键词: 贝纳柯克斯体, Q热立克次体, 慢性Q热, 椎体骨髓炎, 药学监护

Abstract: Objective To explore the starting point where clinical pharmacists can carry out pharmaceutical care for patients with special infections by studying one case of Coxiella burnetii vertebral osteomyelitis. Methods Clinical pharmacists participated in the treatment of one case of lumbar spine infection caused by Coxiella burnetii, assisted clinicians in analyzing the patient's history and etiology, proposed medications with sensitive drugs, provided sustainable pharmaceutical care for the patient, got involved in evaluating the therapeutic effect, and kept adjusting the drug treatment plans. Results and Conclusion Clinical pharmacists assisted doctors in opting for medications and ensuring stable improvement of the patient' conditions. Clinical pharmacists can do much to ensure the safety of medications by participating in a treatment team and starting with rare site infections caused by special pathogens.

Key words: Coxiella burnetii, rickettsia Q fever, chronic Q fever, vertebral osteomyelitis, pharmaceutical care

中图分类号:

R978
R969.3

沈江华, 孔超, 潘福敏, 褚燕琦. 1例贝纳柯克斯体椎体骨髓炎患者的药学监护[J]. 中国药物警戒, 2024, 21(10): 1166-1168.

SHEN Jianghua, KONG Chao, PAN Fumin, CHU Yanqi. Pharmaceutical care of a case with vertebral osteomyelitis of Coxiella burnetiid[J]. Chinese Journal of Pharmacovigilance, 2024, 21(10): 1166-1168.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://zgywjj.magtechjournal.com/CN/10.19803/j.1672-8629.20240221

https://zgywjj.magtechjournal.com/CN/Y2024/V21/I10/1166

参考文献

[1] XU Q, HAN W, CAI Y, et al.A case report of the metagenomic next-generation sequencing for timely diagnosis of a traveler with nonspecific febrile Q fever[J]. Heliyon, 2024, 10(13): e33649.
[2] FU JX, PI SN, CHEN YP.Two cases of chronic Q fever endotitis in Shenzhen[J]. Chin J Infect Dis(中华传染病杂志), 2023, 41(8): 538-539.
[3] SUN HN, REN HX, HE YC.A case of Q fever infection with Coxiella burnetii endocarditis[J]. Infect Dis Info(传染病信息), 2023, 36(1): 90-93.
[4] YANG CF, ZHU S, KANG FK.Coxiella burnetii in periprosthetic joint infection: a case and systematic review[J]. Chin J Orthop(中华骨科杂志), 2023, 43(3): 185-190.
[5] GHANEM-ZOUBI N, KARRAM T, KAGNA O, et al.Q fever vertebral osteomyelitis among adults: a case series and literature review[J]. Infect Dis Nor, 2021, 53(4): 231-240.
[6] VIRK A, MAHMOOD M, KALRA M, et al. Coxiella burnetii multilevel disk space infection, epidural abscess,vertebral osteomyelitis secondary to contiguous spread from infected abdominal aortic aneurysm or graft: report of 4 cases acquired in the US and review of the literature[J]. Open Forum Infect Dis, 2017, 4(4): ofx192.
[7] KOEHLER LM, KLOPPERT B, HAMANN HP, et al.Comprehensive literature review of the sources of infection and transmission routes of Coxiella burnetii, with particular regard to the criteria of “evidence-based medicine”[J]. Comp Immunol Microbiol Infect Dis, 2019, 64: 67-72.
[8] CHERRY CC, NICHOLS HK, BESTUL NC, et al.Acute and chronic Q fever national surveillance - United States, 2008-2017[J]. Zoonoses Public Health, 2022, 69(2): 73-82.
[9] LEAHEY PA, TAHAN SR, KASPER EM, et al. Chronic Q-fever (coxiella burnetii) causing abdominal aortic aneurysm and lumbar osteomyelitis: a case report[J]. Open Forum Infect Dis, 2016, 3(1): ofv185.
[10] DORFMAN K, ERAN A, GHANEM-ZOUBI N.Q fever vertebral osteomyelitis complicating vertebroplasty[J]. Rambam Maimonides Med J, 2021, 12(1): 10430.
[11] VAN ROEDEN SE, WEVER PC, KAMPSCHREUR LM, et al.Chronic Q fever-related complications and mortality: data from a nationwide cohort[J]. Clin Microbiol Infect, 2019, 25(11): 1390-1398.
[12] MELENOTTE C, PROTOPOPESCU C, MILLION M, et al.Clinical features and complications of coxiella burnetii infections from the french national reference center for Q fever[J]. JAMA Netw Open, 2018, 1(4): e181580.
[13] WAELBERS V, DESMET S, DE MUNTER P, et al. Vertebral osteomyelitis or infected abdominal aortic endograft? A rare case of Q fever[J]. Ann Vasc Surg, 2020, 67: 03.018
[14] SUN XX, ZHU L, CHEN W.Research progresson diagnostic techniques for Q fever[J]. China Animal Health Inspection(中国动物检疫), 2019, 36(5): 57-60.
[15] MELENOTTE C, MILLION M, RAOULT D.New insights in Coxiella burnetii infection: diagnosis and therapeutic update[J]. Expert Rev Anti Infect Ther, 2020, 18(1): 75-86.
[16] BUIJS SB, VAN ROEDEN SE, VAN WERKHOVEN CH, et al.The prognostic value of serological titres for clinical outcomes during treatment and follow-up of patients with chronic Q fever[J]. Clin Microbiol Infect 2021, 27(9): 1273-1278.
[17] BUIJS SB, WEEHUIZEN JM, OOSTERHEERT JJ, et al.Chronic Q fever vertebral osteomyelitis, an underrecognized clinical entity[J]. Infect Dis (Lond), 2021, 53(4): 241-242.

1例贝纳柯克斯体椎体骨髓炎患者的药学监护

Pharmaceutical care of a case with vertebral osteomyelitis of Coxiella burnetiid

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	张彩霞, 周易, 谭璐, 陈文明, 柳阳, 游禹. 1例脓毒血症继发肺曲霉菌感染患者的药学监护[J]. 中国药物警戒, 2024, 21(9): 1064-1067.
[2]	严妍, 刘乃一, 乔玲, 张毅, 杨晨. 别嘌醇片诱导的超敏反应综合征致暴发性1型糖尿病1例分析[J]. 中国药物警戒, 2024, 21(9): 1068-1070.
[3]	张乾, 恽渊, 何恋. 1例利培酮致高泌乳素血症患者的药学监护[J]. 中国药物警戒, 2024, 21(8): 936-938.
[4]	林彦馨, 刘艳辉, 董婧, 姚佳晨, 李文艳. 1例伊立替康致结肠癌患者急性肝损伤的药学监护[J]. 中国药物警戒, 2024, 21(6): 693-696.
[5]	黎海燕, 杨忠旭, 刘跃昆, 王丽虹. 1例甲氨蝶呤治疗异位妊娠致严重不良反应患者的药学监护[J]. 中国药物警戒, 2024, 21(4): 454-456.
[6]	吉秋霞, 金剑, 章斌. 特瑞普利单抗免疫相关不良事件药学监护[J]. 中国药物警戒, 2024, 21(3): 346-348.
[7]	张夏兰, 袁静, 吴斌, 秦媛媛. 甲磺酸阿帕替尼在恶性肿瘤患者的用药特征分析[J]. 中国药物警戒, 2023, 20(8): 927-932.
[8]	王然, 李轶凡, 刘小艳, 冯欣. 1例妊娠期药物暴露风险的药学监护[J]. 中国药物警戒, 2023, 20(8): 933-934.
[9]	刘婧, 夏亮, 张世杰. 1例多元药物过敏急性胰腺炎患者行药物激发试验的药学监护[J]. 中国药物警戒, 2023, 20(7): 822-824.
[10]	杨岩, 周德喜, 吴欣俐, 薛淑雅, 丁海华, 张泉, 张云玲. 84例新型抗肿瘤药品不良反应报告分析[J]. 中国药物警戒, 2023, 20(3): 334-338.
[11]	姚鑫, 葛秋格, 李亚敏, 王一帆, 李媛媛, 刘志强. 2018~2022年某院新型抗肿瘤药物消化系统不良反应分析[J]. 中国药物警戒, 2023, 20(11): 1273-1278.
[12]	郑金凤, 王景红. 1例多药联用致室性心律失常的药学监护[J]. 中国药物警戒, 2023, 20(11): 1279-1281.
[13]	苏甦, 伍诗琪, 张青霞, 闫素英. 1例吲达帕胺致粒细胞缺乏症患者的药学监护[J]. 中国药物警戒, 2023, 20(11): 1282-1285.
[14]	王燕婷, 张媛媛, 陈怡然, 孙捷, 朱宇, 杨荔艳, 吴知桂, 申丽君, 程敏, 李国辉. 1例恶性肿瘤患者抗感染与抗肿瘤治疗的平衡抉择及药学监护[J]. 中国药物警戒, 2023, 20(10): 1168-1172.
[15]	王祺茹, 左丽, 杜琼, 叶玲, 阮聪, 翟青, 徐蕊. 1例奥拉帕利致Ⅳ度骨髓抑制患者的药学监护[J]. 中国药物警戒, 2023, 20(10): 1176-1180.